Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) FCF Margin (2020 - 2023)

Historic FCF Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 165.35%.

  • Candel Therapeutics' FCF Margin rose 229346500.0% to 165.35% in Q4 2023 from the same period last year, while for Dec 2023 it was 1337.23%, marking a year-over-year increase of 250466500.0%. This contributed to the annual value of 1293.73% for FY2024, which is 434900.0% up from last year.
  • As of Q4 2023, Candel Therapeutics' FCF Margin stood at 165.35%, which was up 229346500.0% from 1331.99% recorded in Q3 2023.
  • Over the past 5 years, Candel Therapeutics' FCF Margin peaked at 1799.18% during Q1 2023, and registered a low of 30964.52% during Q3 2022.
  • Moreover, its 4-year median value for FCF Margin was 16069.35% (2021), whereas its average is 14192.42%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -141354800bps in 2021, then soared by 322965000bps in 2023.
  • Over the past 4 years, Candel Therapeutics' FCF Margin (Quarter) stood at 12480.65% in 2020, then crashed by -48bps to 18522.58% in 2021, then fell by -25bps to 23100.0% in 2022, then skyrocketed by 99bps to 165.35% in 2023.
  • Its FCF Margin was 165.35% in Q4 2023, compared to 1331.99% in Q3 2023 and 1143.48% in Q2 2023.